fda warning letter compounding semaglutide news September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns – Partnership for Safe Medicines Some people are overdosing on

Tirzepatide versus semaglutide In the direct head-to-head comparison, the 1-year risk of the primary endpoint including all-cause mortality was 1.3% (95% CI 1.2% to 1.5%) for tirzepatide and 1.3% (95% CI 1.2% to 1.5%) for semaglutide, resulting in a risk difference of 0.0% (95% CI 0.2% to 0.2%) and an HR of 1.06 (95% CI 0.95 to 1.18) (Fig

This has been reinforced by anti-addiction findings for GLP-1s

But theres a limit

Lifestyle Changes: Diet quality, calorie intake, and exercise still play a critical role

Finally, in cases where volume contraction is not the obvious mechanism of acute kidney injury, the possibility of acute interstitial nephritis should be considered

Key Considerations for Patients on Weight Loss Medications (Mounjaro/Wegovy) Before Surgery Many patients are using GLP-1 medications such as Semaglutide (Wegovy) or Tirzepatide (Mounjaro) to support weight loss